Background

Rare genetic diseases worldwide cause lifelong suffering for patients and their families, and pose a significant public health challenge due to the substantial medical costs they incur. In particular, the Middle East, including the United Arab Emirates (UAE), has a high rate of consanguineous marriages, approaching 50% due to historical and cultural influences, which in turn leads to a high incidence of autosomal recessive genetic diseases. Existing screening tests have been limited to specific blood disorders such as beta-thalassemia and sickle cell anemia, making it difficult to prevent most rare diseases. The fact that parents, who are both carriers of a genetic mutation, may be asymptomatic and unaware of their carrier status, contributes to the transmission of genetic diseases. In this context, there has been a growing need for a paradigm shift in preventive medicine, utilizing next-generation technologies to identify genetic risks early and strengthen pre-emptive management.

Key Findings

In line with these public health needs, a study analyzing the results of the UAE's pioneering genetic screening program was published in the international journal, the New England Journal of Medicine (NEJM). The researchers conducted a detailed analysis of the initial data from the national genome screening program implemented in Dubai. This program targeted 1,000 Emirati couples who were about to marry. Unlike conventional simple blood tests, the program applied next-generation sequencing (NGS) to decode the entire nucleotide sequence of 782 genes associated with autosomal recessive genetic diseases in the prospective couples. This is the key feature of the program.

As a result of the analysis, 80 couples, representing 8% of the total subjects, were identified as carrier pairs sharing a pathogenic variant in the same gene. This means that their offspring have a 25% chance of developing a serious genetic disease. Among the identified genetic variants, blood disorders, including thalassemia, accounted for the highest proportion. However, non-blood-related recessive genetic variants also accounted for a significant proportion, representing 59% of the high-risk couples. This figure demonstrates that the previous limited screening methods failed to prevent many genetic risks.

Notably, the behavior of the couples who received a high-risk diagnosis is worth noting. Among the high-risk couples, 80% decided to proceed with the marriage as planned, but to utilize in vitro fertilization (IVF) and preimplantation genetic testing (PGT) to prevent the transmission of the disease. These couples are exploring ways to plan for a safe delivery through government-supported programs. The remaining 20% chose to discontinue the marriage process and seek another partner in order to avoid the genetic risk.

Significance and Prospects

This study is significant in that it provides data-driven evidence of the practical preventive effects that can be achieved by introducing large-scale genome analysis at the national level as a mandatory pre-marital test. In particular, it has paved the way for a shift from public health policies that have relied on family history to a personalized precision medicine system based on genetic information. This leads to a reduction in social medical costs in the long term by preventing the birth of children with genetic diseases. Furthermore, it is likely to serve as a policy model for neighboring Middle Eastern countries with similar cultural backgrounds.

However, there are many challenges to be addressed before this program can be expanded globally. First and foremost, technological advancements are needed to reduce the cost of testing and shorten the result analysis time. Furthermore, it is imperative to train professional genetic counselors who can properly explain genomic information to high-risk couples and prevent stigma and discrimination. Strict security measures and legal safeguards to prevent the leakage of genetic information will also be a major factor in the success of national preventive medicine.